Denver Myeloma Roundtable image

Denver Myeloma Roundtable

Sep 12, 2026
08:00AM - 02:30PM MDT
Sheraton Denver Downtown Hotel
1550 Court Pl, Denver, CO 80202, USA
$ 25
Overview

Join us for the Denver Myeloma Roundtable on September 12th to hear directly from leading myeloma experts about the latest in treatment and research. Designed specifically for patients and caregivers, the event includes patient-friendly presentations, breakout sessions for newly diagnosed and relapsed/refractory patients, and a dedicated faculty Q&A with plenty of time to ask questions.

  • Registration & breakfast 8:00 am

  • Program: 9:00 am - 2:30 pm

  • Location: Sheraton Denver Downtown Hotel, Majestic Ballroom

  • Breakout sessions & meals: Vail Ballroom

  • Included: Breakfast, lunch, refreshments, and parking

  • Nearest airport: Denver International Airport (DEN)

  • Hotel accommodations: A special room rate is available for Roundtable attendees at the Sheraton Denver Downtown Hotel. Hotel accommodations are not included with registration. Reserve your room here by August 24, 2026, to receive the special Roundtable rate.

Unable to attend in person? Register to receive access to the event recording.

This event will not be livestreamed. The recording will be available approximately one week after the event, and registered individuals will receive an email when it is ready.

Make it a weekend

Traveling to Denver for the Roundtable? Here are a few recommendations:

Questions?

For registration questions, contact us at  +1 800 709 1113 or email us at support@healthtree.org

To ensure we can continue providing you with excellent venues, quality meals, and a valuable experience at our Roundtable meetings, we're introducing a modest registration fee. If the fee is a financial burden, please contact us for a promotional code to waive the cost.

User uploaded media
Agenda
8:00 AM
Breakfast & Registration
9:00 AM
Welcome and Introduction
Jenny Ahlstrom
9:15 AM
Rethinking Early Myeloma Care
Jorge Monge, MD
  • Evolving strategies in smoldering multiple myeloma (SMM)
  • Personalizing care across precursor and newly diagnosed disease
9:45 AM
The CAR T Revolution: Shifting the Paradigm Upstream
Tara K. Gregory, MD
  • Overview of FDA-approved CAR-T therapies and how they are used today
  • What’s changing in access, design, and earlier CAR T use
10:15 AM
Break
10:30 AM
Bispecific Antibodies: Bringing Immunotherapy Within Reach
Peter A. Forsberg, MD
  • The what, when, who, and how of bispecific antibodies
11:00 AM
HealthTree Cure Hub
Jenny Ahlstrom
11:15 AM
Breakout Sessions
Tara Gregory, MD & Kate Mimken, RN, BSN, FNP-C

MRD Matters: Using Minimal Residual Disease to Guide Decisions, Tara Gregory, MD

OR

Staying Strong During Treatment: Managing Side Effects & Preventing Infection, Kate Mimken, RN, BSN, FNP-C

12:00 PM
Lunch
1:00 PM
Redefining What’s Possible: The Future of Myeloma Therapy,
Jeffrey V Matous, MD
  • Looking forward in myeloma care with new targets, new administrations, and new technologies
  • CELMoDs, in vivo CAR T, antibody drug conjugates, and more 
1:30 PM
Round Table Audience Q&A with Faculty
  • Tara Gregory MD
  • Jorge Monge, MD
  • Peter Forsberg, MD
  • Jeffrey V Matous, MD
  • Kate Mimken, RN, BSN, FNP-C
2:15 PM
Help with HealthTree
Speakers & Moderators
Healthtree contact Jenny Ahlstrom

Jenny Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Healthtree contact Tara K. Gregory, MD

Tara K. Gregory, MD

Tara Gregory, MD, is a medical oncologist at the Colorado Blood Cancer Institute and Co-Director of the Plasma Cell Dyscrasia Program. She specializes in the treatment of multiple myeloma, amyloidosis, and other plasma cell disorders, with expertise in stem cell transplantation and cellular therapies. Dr. Gregory is actively involved in clinical research and has dedicated her career to advancing treatment options and improving outcomes for patients with blood cancers.
Healthtree contact Jorge Monge, MD

Jorge Monge, MD

Jorge Monge, MD, is a hematologist and medical oncologist at the University of Colorado specializing in multiple myeloma and other plasma cell disorders. He is actively involved in clinical research focused on advancing innovative therapies and improving outcomes for patients with blood cancers. Dr. Monge is committed to providing personalized, patient-centered care while helping bring the latest treatment advances to the myeloma community.
Healthtree contact Peter A. Forsberg, MD

Peter A. Forsberg, MD

Peter A. Forsberg, MD, is a hematologist and medical oncologist at the Colorado Blood Cancer Institute specializing in multiple myeloma and other plasma cell disorders. He serves as Director of Translational Research and is actively involved in clinical trials focused on developing new treatment options for patients with blood cancers. Dr. Forsberg is dedicated to advancing innovative therapies while providing compassionate, patient-centered care.
Healthtree contact Jeffrey V Matous, MD

Jeffrey V Matous, MD

Jeffrey V. Matous, MD, is a hematologist and medical oncologist at the Colorado Blood Cancer Institute with a special focus on multiple myeloma and other plasma cell disorders. He has been a leader in clinical research for more than two decades, helping bring innovative therapies and clinical trials to patients with blood cancers. Dr. Matous is dedicated to advancing myeloma care while providing personalized, patient-centered treatment.
Healthtree contact Kate Mimken, RN, BSN, FNP-C

Kate Mimken, RN, BSN, FNP-C

Kate Mimken, RN, BSN, MSN, FNP-C, is a nurse practitioner at the Colorado Blood Cancer Institute with extensive experience caring for patients with blood cancers. Throughout her oncology career, she has focused on helping patients navigate treatment, manage side effects, and maintain quality of life. Kate is passionate about patient education and empowering individuals and families with practical information to support their care journey.